Literature DB >> 12223985

Antistreptococcal response is exaggerated in children with familial Mediterranean fever.

F Yalçinkaya1, E Ince, T Uçar, N Ozkaya, M Tekin, A H Elhan, E Tutar, D H Güriz, D Aysev, R Gökdemir, U Doğru, N Tümer.   

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disorder. Although the pathogenesis of the disease is not yet completely understood, enhanced acute-phase responsiveness is considered to be one of the most important mechanisms. The presence of high levels of antistreptolysin O (ASO) antibodies and streptococcus-associated diseases, such as acute poststreptococcal glomerulonephritis (AGN) and acute rheumatic fever (ARF), has been reported in patients with FMF. In order to better understand the effect of FMF on antistreptococcal antibody response, we measured ASO and antideoxyribonuclease B (anti-DNAse B) levels in patients with FMF and compared them with those in healthy controls. The study consisted of two parts. In the first step, antistreptococcal antibody levels were analysed in 44 patients with FMF and 165 healthy children who had no history or clinical evidence of upper respiratory tract infection (URTI) for the last 4 months. In the second step, antistreptococcal antibody levels were measured in 15 patients with FMF and 22 healthy controls in response to documented group A beta-haemolytic streptococcal pharyngitis. In the first part of the study, ASO and anti-DNAse B levels in patients with FMF were found to be significantly higher than those in healthy controls (P<0.001). In the second part, ASO and anti-DNAse B titres were found to be significantly higher in patients with FMF than in controls (P<0.001 and <0.05, respectively) 4 weeks after a positive throat culture. We concluded that patients with FMF have an exaggerated response to streptococcal antigens and might be prone to poststreptococcal non-suppurative complications, such as ARF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223985     DOI: 10.1007/s100670200101

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

1.  Mediterranean fever (MEFV) gene mutation frequency is not increased in adults with rheumatic heart disease.

Authors:  Ismail Simsek; Cem Koz; Nurcan Basar; Ismail Sari; Hakan Erdem; Salih Pay; Bunyamin Kisacik; Muhterem Bahce; Ayhan Dinc
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

2.  Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.

Authors:  Guzide Aksu; Can Ozturk; Kaan Kavakli; Ferah Genel; Necil Kutukculer
Journal:  Clin Rheumatol       Date:  2006-05-24       Impact factor: 2.980

Review 3.  Coexistence of vasculitides with familial Mediterranean fever.

Authors:  Kenan Aksu; Gokhan Keser
Journal:  Rheumatol Int       Date:  2011-03-10       Impact factor: 2.631

Review 4.  Vascular comorbidities in familial Mediterranean fever.

Authors:  Z Birsin Ozçakar; Fatoş Yalçınkaya
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

Review 5.  Non-canonical manifestations of familial Mediterranean fever: a changing paradigm.

Authors:  Donato Rigante; Giuseppe Lopalco; Giusyda Tarantino; Adele Compagnone; Michele Fastiggi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-03-13       Impact factor: 2.980

6.  Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and IgA nephropathy.

Authors:  Keisuke Sugimoto; Shinsuke Fujita; Tomoki Miyazawa; Mitsuru Okada; Tsukasa Takemura
Journal:  Pediatr Nephrol       Date:  2012-09-02       Impact factor: 3.714

7.  Coexisting Diseases in Patients with Familial Mediterranean Fever.

Authors:  Farhad Salehzadeh; Afsaneh Enteshari Moghaddam
Journal:  Open Access Rheumatol       Date:  2020-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.